Dr. Peter Klaffenbach has been in transdermal drug delivery systems development for over 20 years and is now in charge of pharmaceutical development of LTS. Prior to joining LTS, Peter was managing director at the German drug delivery company Labtec (now tesa-Labtec) and head of pharmaceutical development at 3M drug delivery in Germany.
1. Why did you decide to do a webinar with Business Review Webinars?
Actually, my marketing department thought that a webinar could be the right platform to reach an interested audience of professionals to share our knowledge of transdermal drug delivery. Patch technology is still a niche – conferences are rare and expensive. Webinars represent a modern and effective way to discuss these kinds of topics with the industry.
2. What are you looking forward to explaining to the audience?
I’m looking forward to share our vision. That is that transdermal systems are not only an excellent option for lifecycle management of established APIs, but the technology should also be considered very early in NCE development and considered as a first line dosage form.
3. What is the ideal outcome you would like from doing the webinar?
If some of the attendees would consider a patch as an alternative to a tablet as part of the initial drug product development, this would be a great outcome.
4. Where is your favourite place in the world and why?
Anywhere, as long it is underwater. Why? Because underwater we need to refocus our senses and we can enjoy life in three dimensions.
5. What motivates you?
To help patients to deal with their problems a little more easily by providing solutions that meet their needs.
Peter will be presenting his webinar ‘Transdermal Drug Delivery: Is it feasible for your drug?‘ on the 25th November at 10am New York/3pm London. Click here to read more and register.